Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q2 2022 Earnings Presentation
22 slides from Q-linea Ab's earnings presentation, Jul 14, 2022
Slide 1: Future Proof Healthcare - Presentation Q2(22)
FUTURE PROOF HEALTHCARE A sustainable healthcare for a new generation Presentation Q2(22) Jonas Jarvius, CEO Anders Lundin, CFO/IR
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea 2nd quarter: Introduction to the company
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 2nd quarter Q-linea is developing disruptive solutions for faster Lead product ASTar® infectious disease diagnostics, first product targeting sepsis Introduction to the company 175 employees & consultants at quarter end V
Slide 4: Time to actionable results is important
Time to actionable results is important Sepsis is the most common cause of death in our hospitals More common that lung + prostate + breast-cancer combined Accounts for approximate 30% of all deaths in the hospital Most expensive condition to treat in the US. >27B USD1) Time to correct treatment is
Slide 5: Rapid AST & a broad antimicrobial panel matters
Rapid AST & a broad antimicrobial panel matters: ASTar can provide up to 48 hours faster actionable results Transportation of blood culture from patient to laboratory: 1 – 24+ hours DAY 1 DAY 2 DAY 3 DAY 4 Plates are streaked CURRENT WORKFLOW Gram Susceptibility Patient to perform a Colony blood dra
Slide 6: Health economic benefits of 24 hour faster diagnostics
Health economic benefits of 24 hour faster diagnostics Less pressure for Cost savings Lower mortality resistance and superinfections Up to 25% Up to 40% ~$2,500 – $20,000 reduction of C. difficile lower mortality rates1) cost savings per patient3) infections2) ASTar can provide up to 48 hours faster
Slide 7: ASTar – a platform designed to save lifetimes
ASTar – a platform designed to save lifetimes Developed together with our future customers Easy to use Comprehensive • Fully automated • Large antibiotic panel • ~2 min hands-on time • Long concentration • Load-and go workflow ranges • Fastidious and non- fastidious bacteria Fast • Support additiona
Slide 8: Easy to use
Easy to use User friendly & 24/7 availability ASTar enables anyone at the lab to load sample anytime and enables lab personnel to do more in less time Click “start” Scan barcode Add sample Load AST disc Add sample barcode Click “Start run” Source: Company information and webpage 8
Slide 9: ASTar provides excellent performance
ASTar provides excellent performance Broad panel enabling actionable results Excellent and accurate data from the CE-IVD clinical study FDA and ISO requirements1,2) The ASTar® Instrument and ASTar® BC G- Kit offer the Essential agreement = Same MIC value as reference broadest combination of antimicr
Slide 10: High throughput and flexible solution
High throughput and flexible solution High throughput & flexible Our ambition was the most user friendly and capable system Up to 12 patient samples in parallel = Fully automatic Semi automatic Consumables stored at room temp and a small insert at -20°C. Compatible with small and large (e.g. urine)
Slide 11: Q-linea technology within infectious disease diagnostics
Q-linea technology within infectious disease diagnostics Q-linea technology is covered by 24 patent families Blood culturing Identification Susceptibility testing Mass spec Molecular TRADITIONAL TECHNOLOGY Podler® ASTrID® ASTar ASTrea™ ® Q-LINEA TECHNOLOGY Highly multiplexed Portable blood culturing
Slide 12: A new era needs a new reference
A new era needs a new reference Our goal is that ASTar becomes the rAST reference From blood culture bottles E.Coli – Pip/Tazo E.Coli – Ceftazidime S.Aureus– Gentamicin 4x Reported MIC 2x Q-linea ASTar analysis 1x 0.5x More complex sample and 6h analysis time 0.25x 10 different positive blood cultur
Slide 13: Key highlights second quarter
Key highlights second quarter Two incredibly successful tradeshows ASTar was presented by both Q-linea and Thermo Fisher Scientific at ECCMID in Lisbon and ASM in Washington Very successful conference generating a high number of leads, interest from large institutions and strategic company interest.
Slide 14: Key highlights second quarter: closer to the US market
Key highlights second quarter ASTar is coming closer to the US market Q-linea’s ASTar classified as a breakthrough device by the FDA during the first quarter Q-linea submitted the 510(k) application to the FDA to gain US market authorization 9th June 14 14 Source: Company information.
Slide 15: Steady progress towards IVDR & interest for Podler
Key highlights second quarter Steady progress towards IVDR & strengthened interest for Podler The ASTar instrument successfully achieved IVDR status in May Q-linea has been working for many years towards IVDR certification and a major milestone was met when the instrument achieved IVDR status. Next
Slide 16: A pivotal development
Key highlights second quarter A pivotal development For the first time in 14 years, we now foresee a decrease or leveling of the staff in Q-linea Historically we have used a high number of consultants in order to handle peak load and reach key milestones. After reaching both the IVDR submission and
Slide 17: The effects of the Corona pandemic on Q-linea
The effects of the Corona pandemic on Q-linea The pandemic is followed carefully but has currently minor effects on operations We are now working according to the “new normal” after the pandemic but follow the development of the pandemic closely to enable rapid changes if needed. Future possible eff
Slide 18: Income statement second quarter
Income statement second quarter Net sales in the second quarter amounted to SEK 4.1 million (4.3). Goods that have been expensed in the second quarter amounted SEK -10.4 (-6.4) million. Operating result totalled SEK -73.1 million (-68.2). The company reported a loss after tax of SEK -74.0 million (-
Slide 19: Balance sheet items at the end of second quarter
Balance sheet items at the end of second quarter Cash and cash equivalents amounted to SEK 19.6 million (15.1) Total Short-term investments amounted SEK 100.2 million (150.9), whereof the current portion of non-current assets (listed bonds) SEK 74.8 million (59.7). Non-current assets, listed bonds S
Slide 20: Cash flow statement second quarter
Cash flow statement second quarter Cash flow from operating activities SEK -69.1 million (-45.0). Decrease in cash outflow from operating activities mainly due to less favourable changes in the working capital compared to the same quarter last year and lower Operating result. Cash flow from investin
Slide 21: Thank you
Looking forward to an exciting continuation of 2022 Q-linea wants to contribute to a healthier society by future- proofing a new generation of healthcare professionals, labs and hospitals. Thank you 21
Slide 22: Key highlights after period end
Key highlights after period end ECCMID was a total success 22 22 Source: Company information.